Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Viracta Therapeutics  (Stock symbol: VIRX ) Merged with Viracta Therapeutics (2021 )

395 Oyster Point Blvd. #400
South San Francisco, CA 94080
USA
(650)-266-3500
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) H. Ward Wolff (Sangamo Therapeutics Former CFO) James W. Young (Viracta Therapeutics Former CEO) Barry J. Simon (Nantkwest Former President) Sam Murphy (Shenzhen Salubris Pharmaceutical VP Head of Business Development) Michael Huang (Taiwania Capital Management Company Managing Partner) Thomas E. Darcy (Tocagen Former CFO) Roger J. Pomerantz (ContraFect CEO/Chairman) Nicole Onetto (Ontario Institute for Cancer Research Former Chief Scientific Officer) Gur Roshwalb (aMoon Managing Director) Stephen Rubino (Celyad Oncology Chief Business Officer)
Former outside board: Edward Hurwitz (Alta Partners Director) Jonathan J. MacQuitty (Abingworth Management Partner) Steven B. Ketchum (Viracta Therapeutics SVP R&D) James Wells (Viracta Therapeutics Former VP Scientific Officer) Homer L. Pearce (Eli Lilly Former VP Cancer Research) David C. Stump (Human Genome Sciences SVP Drug Development) Dayton Misfeldt (Bay City Capital Investment partner) Matthew K. Fust (Jazz Pharmaceuticals CFO) Helen S. Kim (NGM Biopharmaceuticals Chief Business Officer) Steve R. Carchedi (Cornerstone Pharmaceuticals President/CEO) Anthony B. Evnin (Venrock Associates) Stephen A. Fodor (Affymetrix CEO) Steven D. Goldby (Accelrys CEO) Russell Hirsch (Mayfield Fund);  Jonathan S. Leff (Warburg Pincus Partner)
Company

Business description: Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
Partners include: JohnsonAndJohnson PRD;  Dainippon Pharmaceutical;  MerckAndCo.
Capital

Rounds: 4
Recent Fundings: Oct 2005
Capital raised: 96.3M
Last Round: 14.0M
Ownership: Merged with Viracta Therapeutics (2021 )
Stock Symbol: VIRX
VCs include: Abingworth ManagementMayfield FundSkyline VenturesVenrock AssociatesWarburg Pincus;  Credit Suisse First Boston;  Lombard Odier;  Global Biomedical Partners;  Havingworth;  International Biotechnology Trust
Angels/other VCs: Alejandro Zaffaroni
Corporate investors: Bristol-Myers;  New Medical Technologies;  Biogen Idec

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2021
Sector: Biotech
Year Founded: 1998
Headcount: 51-75 as of Jun 2021
Rounds: 4
Recent Fundings: Oct 2005
Capital Raised: 96.3M
Last Round: 14.0M
Ownership: Merged with Viracta Therapeutics (2021 )
Stock Symbol: VIRX